betaxolol has been researched along with Glaucoma in 101 studies
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe the safety profile and clinical response on elevated intraocular pressure (IOP) of betaxolol hydrochloride ophthalmic suspension 0." | 9.14 | Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. ( Dickerson, JE; Gross, RD; Krishnadas, SR; Netland, PA; Plager, DA; Robin, AL; Sathyan, P; Scheib, SA; Scott, H; Sood, D; Vijaya, L; Whitson, JT, 2009) |
| "To describe the safety and clinical response on elevated intraocular pressure (IOP) of brinzolamide and levobetaxolol in pediatric patients under 6 years of age." | 9.13 | Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. ( Bergamini, MV; Dickerson, JE; Gross, RD; Hua, SY; Landry, TA; Roarty, JD; Robin, AL; Scheib, SA; Scott, H; Vijaya, L; Whitson, JT; Woodside, AM, 2008) |
| "To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial." | 9.10 | Results of the betaxolol versus placebo treatment trial in ocular hypertension. ( Bunce, C; Franks, W; Garway-Heath, D; Hitchings, R; Kamal, D; O'Sullivan, F; Ruben, S; Viswanathan, A, 2003) |
| "We compared the effect of selective (betaxolol) and nonselective (timolol) beta-adrenergic blocking drugs on flow velocities (as determined by color Doppler imaging) in orbital vessels in 13 patients with normal-tension glaucoma (mean age, 62 +/- 3 years; mean intraocular pressure, 15 +/- 2 mm Hg)." | 9.08 | Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. ( Cantor, LB; Harris, A; Katz, LJ; Martin, BJ; Sergott, RC; Spaeth, GL, 1995) |
| "In a double-masked study, 40 patients with primary open-angle glaucoma were randomly assigned to treatment with betaxolol 0." | 9.07 | Influence of betaxolol and timolol on the visual fields of patients with glaucoma. ( Flammer, J; Messmer, C; Stümpfig, D, 1991) |
| "The extent of impairment of respiratory function in a group of 52 elderly, glaucomatous patients receiving topical timolol therapy was investigated." | 9.07 | Unsuspected bronchospasm in association with topical timolol--a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? ( Chau, G; Diggory, P; Heyworth, P; McKenzie, S; Sharma, A, 1994) |
| "Betaxolol, a cardioselective beta 1-adrenergic antagonist, was used in a clinical trial in nine patients with glaucoma and chronic obstructive airways disease to assess its patient acceptance, and its effect on intraocular pressure, respiratory function, corneal and tear function." | 9.06 | Betaxolol eye drops as a safe medication to lower intraocular pressure. ( Brooks, AM; Gillies, WE; West, RH, 1987) |
| "In a randomized, double-masked study, 41 patients with primary open-angle glaucoma or ocular hypertension were treated with betaxolol 0." | 9.06 | A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. ( Feghali, JG; Kaufman, PL; Mandell, AI; Radius, RL, 1988) |
| "Betaxolol is a new antiglaucomatous drug which is blocking solely the beta 1 receptors and in contrast to Timolol may be applied in persons with spastic conditions of the bronchi." | 9.06 | [Use of Betaxolol in patients with glaucoma and chronic nonspecific diseases of the respiratory system]. ( Rojek, A; Sempińska-Szewczyk, J; Swietliczko, I; Toczyska-Rozentryt, E, 1989) |
| "Three hundred fifty-three patients whose intraocular pressure was controlled with a timolol maleate ophthalmic solution were studied." | 9.06 | Changing therapy from timolol to betaxolol. Effect on intraocular pressure in selected patients with glaucoma. Timolol-Betaxolol Study Group. ( Clineschmidt, CM; Kulaga, SF; Tipping, R; Vogel, R, 1989) |
| "To report a case of pulmonary edema associated with the use of ocular metipranolol, a nonselective beta-blocker." | 8.79 | Acute pulmonary edema associated with ocular metipranolol use. ( Johns, MD; Ponte, CD, 1995) |
| ", niosomes) as drug vehicles to enhance the ocular availability of betaxolol hydrochloride for management of glaucoma." | 8.02 | Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma. ( Allam, A; El Badry, M; Eleraky, NE; Elsabahy, M, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 7.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "Inspired by these advance of montmorillonite/chitosan nanoparticles, we envision that the BH-Mt/CS NPs will be a potential carrier for BH, opening up the possible applications in glaucoma therapy." | 7.88 | Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma. ( Chen, Y; Gui, R; Hou, D; Li, J; Ping, Q; Tao, Q; Tian, S; Yang, F; Zang, L; Zhao, Y, 2018) |
| "Enucleated eyes (n = 7) of patients with glaucoma (age range, 27-79 years), without apparent anatomic disruption that would be likely to influence betaxolol absorption and intraocular distribution (exceptions: one pseudophakic, one aphakic) or other disease, were analyzed for betaxolol concentrations after self-administration of 0." | 7.73 | Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. ( Chastain, J; Curtis, M; Dahlin, DC; DeSantis, L; Faulkner, R; Holló, G; McCue, B; Przydryga, J; Sanders, M; Whitson, JT; Wieland, H, 2006) |
| "To evaluate the intraocular pressure (IOP) lowering efficacy and safety of Brinzolamide combined with Betaxolol for the Chinese glaucomatous patients." | 7.73 | [Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol]. ( Fang, M; Ge, J; Huang, S; Minbin, Y, 2005) |
| "To report a case of herpes simplex virus reactivation after starting bimatoprost treatment for glaucoma." | 7.71 | Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. ( Kroll, DM; Schuman, JS, 2002) |
| "Small (1-cc) specimens of Tenon capsule were removed at the time of filtering surgery from 15 glaucoma patients under long-term preoperative topical therapy, nine of whom had been treated with timolol and six of whom had been receiving betaxolol." | 7.70 | Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy. ( Frenzel, H; Khuu, HD; Lam, KW; Sponsel, WE; Terry, S, 1999) |
| "We evaluated the use of topically administered betaxolol, a cardioselective beta-adrenergic blocking agent, in 11 patients (eight women and three men, 40 to 81 years old) who had asthma and severe glaucoma with increased intraocular pressure despite maximally tolerated medical therapy." | 7.67 | Betaxolol in patients with glaucoma and asthma. ( Berry, DP; Drake, MM; Lustgarten, JS; Podos, SM; Van Buskirk, EM; Weinreb, RN, 1986) |
| "Glaucoma is a chronic optic neuropathy in which retinal ganglion cells die over a number of years." | 6.42 | Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. ( Casson, R; Chidlow, G; DeSantis, L; Osborne, NN; Schmidt, KG; Wood, JP, 2004) |
| "Betaxolol is a lipophilic beta-adrenoceptor antagonist relatively selective for beta 1-adrenoceptors with only weak beta 2-blocking activity." | 6.38 | Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. ( Buckley, MM; Clissold, SP; Goa, KL, 1990) |
| "Glaucoma is described, and the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of betaxolol and levobunolol in comparison with timolol are reviewed." | 6.16 | Comparison of ophthalmic beta-blocking agents. ( Lesar, TS, 1987) |
| "Glaucoma is a chronic disease that requires long-term adherence to treatment." | 5.72 | Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction. ( Han, X; Hou, D; Hu, J; Ke, Y; Li, H; Li, W; Lin, H; Liu, H; Rupenthal, ID; Yang, F; Ye, J; Zhao, Y, 2022) |
| "In a double masked randomised clinical trial, 38 eyes from 38 pseudophakic patients over 21 years of age who had significant posterior capsule opacification after phacoemulsification were randomly assigned to receive either betaxolol 0." | 5.51 | The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy. ( Elmi Sadr, N; Paknazar, F; Saber, E, 2022) |
| "Our aim was to study the concentration of betaxolol in plasma after its topical ocular use during the normal 12 hr dosing interval." | 5.31 | Plasma concentration of topically applied betaxolol in elderly glaucoma patients. ( Huupponen, R; Pyykkö, K; Vainio-Jylhä, E; Vuori, ML, 2001) |
| "To investigate the acute effects of brinzolamide, betaxolol, and latanoprost (drugs commonly used in the medical management of glaucoma) on choroidal thickness using enhanced depth imaging optical coherence tomography (EDI-OCT)." | 5.30 | Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness. ( Arslan, MG; Fındık, H; Okutucu, M, 2019) |
| " Very mild eye irritation, which was less than that of betaxolol hydrochloride, was observed particularly with BMO maleate, which is an excellent candidate for safe treatment of glaucoma." | 5.30 | Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma. ( Barros, MD; Bodor, N; Farag, HH; Prokai, L; Somogyi, G; Wu, WM, 1997) |
| "Betaxolol 0." | 5.27 | Long-term betaxolol therapy in glaucoma patients with pulmonary disease. ( Cherniack, R; Drake, MM; van Buskirk, EM; Weinreb, RN, 1988) |
| "To describe the safety profile and clinical response on elevated intraocular pressure (IOP) of betaxolol hydrochloride ophthalmic suspension 0." | 5.14 | Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. ( Dickerson, JE; Gross, RD; Krishnadas, SR; Netland, PA; Plager, DA; Robin, AL; Sathyan, P; Scheib, SA; Scott, H; Sood, D; Vijaya, L; Whitson, JT, 2009) |
| "To describe the safety and clinical response on elevated intraocular pressure (IOP) of brinzolamide and levobetaxolol in pediatric patients under 6 years of age." | 5.13 | Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. ( Bergamini, MV; Dickerson, JE; Gross, RD; Hua, SY; Landry, TA; Roarty, JD; Robin, AL; Scheib, SA; Scott, H; Vijaya, L; Whitson, JT; Woodside, AM, 2008) |
| "To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial." | 5.10 | Results of the betaxolol versus placebo treatment trial in ocular hypertension. ( Bunce, C; Franks, W; Garway-Heath, D; Hitchings, R; Kamal, D; O'Sullivan, F; Ruben, S; Viswanathan, A, 2003) |
| " In a double-masked fashion, each subject's right eye was treated with one of 5 glaucoma medications (brinzolamide 1%, timolol 0." | 5.09 | Does glaucoma medication influence the diameter of the retinal arteriole in the human eye? (A pilot study using the retinal vessel analyser). ( Holló, G; Kóthy, P, 2001) |
| "We compared the effect of selective (betaxolol) and nonselective (timolol) beta-adrenergic blocking drugs on flow velocities (as determined by color Doppler imaging) in orbital vessels in 13 patients with normal-tension glaucoma (mean age, 62 +/- 3 years; mean intraocular pressure, 15 +/- 2 mm Hg)." | 5.08 | Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. ( Cantor, LB; Harris, A; Katz, LJ; Martin, BJ; Sergott, RC; Spaeth, GL, 1995) |
| "The extent of impairment of respiratory function in a group of 52 elderly, glaucomatous patients receiving topical timolol therapy was investigated." | 5.07 | Unsuspected bronchospasm in association with topical timolol--a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? ( Chau, G; Diggory, P; Heyworth, P; McKenzie, S; Sharma, A, 1994) |
| "Fifty-two elderly glaucomatous patients, without a history of asthma or obstructive airways disease, who were using topical timolol for control of intraocular pressure were recruited." | 5.07 | Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. ( Chau, G; Diggory, P; Heyworth, P; Luke, I; McKenzie, S; Sharma, A, 1993) |
| "In a double-masked study, 40 patients with primary open-angle glaucoma were randomly assigned to treatment with betaxolol 0." | 5.07 | Influence of betaxolol and timolol on the visual fields of patients with glaucoma. ( Flammer, J; Messmer, C; Stümpfig, D, 1991) |
| "A double-blind cross-over study was carried out on 15 glaucoma patients so as to verify the effects of three the beta blockers, beta-1 selective betaxolol, non-selective timolol and befunolol an agent with intrinsic sympathomimetic activity on the heart rate, monitored by a Holter apparatus, and with the blood pressure measured in standing and supine positions before and after eight days of topical therapy." | 5.06 | Cardiovascular effects of befunolol, betaxolol and timolol eye drops. ( Altafini, R; Cerin, O; Dorigo, MT; Fracasso, G, 1990) |
| "Betaxolol is a new antiglaucomatous drug which is blocking solely the beta 1 receptors and in contrast to Timolol may be applied in persons with spastic conditions of the bronchi." | 5.06 | [Use of Betaxolol in patients with glaucoma and chronic nonspecific diseases of the respiratory system]. ( Rojek, A; Sempińska-Szewczyk, J; Swietliczko, I; Toczyska-Rozentryt, E, 1989) |
| "Betaxolol, a cardioselective beta 1-adrenergic antagonist, was used in a clinical trial in nine patients with glaucoma and chronic obstructive airways disease to assess its patient acceptance, and its effect on intraocular pressure, respiratory function, corneal and tear function." | 5.06 | Betaxolol eye drops as a safe medication to lower intraocular pressure. ( Brooks, AM; Gillies, WE; West, RH, 1987) |
| "In a randomized, double-masked study, 41 patients with primary open-angle glaucoma or ocular hypertension were treated with betaxolol 0." | 5.06 | A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. ( Feghali, JG; Kaufman, PL; Mandell, AI; Radius, RL, 1988) |
| "To report a case of pulmonary edema associated with the use of ocular metipranolol, a nonselective beta-blocker." | 4.79 | Acute pulmonary edema associated with ocular metipranolol use. ( Johns, MD; Ponte, CD, 1995) |
| " Betaxolol is a relatively selective beta-1 blocker which in most patients is almost as effective as timolol in lowering intraocular pressure, and may be partly additive with dipivefrin." | 4.77 | Betaxolol. ( Goldberg, I, 1989) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 3.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "Inspired by these advance of montmorillonite/chitosan nanoparticles, we envision that the BH-Mt/CS NPs will be a potential carrier for BH, opening up the possible applications in glaucoma therapy." | 3.88 | Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma. ( Chen, Y; Gui, R; Hou, D; Li, J; Ping, Q; Tao, Q; Tian, S; Yang, F; Zang, L; Zhao, Y, 2018) |
| "In this study, the various antiglaucoma drugs including betaxolol, timolol, levobunolol, carteolol, brimonidine, dipivefrin, dorzolamide, brinzolamide, latanoprost, unoprostone, and pilocarpine were used to investigate the effects of cellular cytotoxicity in cultured bovine corneal endothelial cells." | 3.74 | Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. ( Hong, SJ; Wang, HZ; Wu, KY, 2007) |
| "In the present study, we investigated the direct effects of antiglaucoma drugs (timolol, betaxolol, pilocarpine, and latanoprost) on N-methyl-D-aspartate (NMDA)-receptor function using a Xenopus oocytes expression system and electrophysiological techniques." | 3.74 | Direct inhibition of N-methyl-D-aspartate (NMDA)-receptor function by antiglaucomatous beta-antagonists. ( Kubota, T; Morita, H; Nagata, T; Tawara, A; Toyohira, Y; Tsutsui, M; Ueno, S; Yanagihara, N, 2008) |
| "Enucleated eyes (n = 7) of patients with glaucoma (age range, 27-79 years), without apparent anatomic disruption that would be likely to influence betaxolol absorption and intraocular distribution (exceptions: one pseudophakic, one aphakic) or other disease, were analyzed for betaxolol concentrations after self-administration of 0." | 3.73 | Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. ( Chastain, J; Curtis, M; Dahlin, DC; DeSantis, L; Faulkner, R; Holló, G; McCue, B; Przydryga, J; Sanders, M; Whitson, JT; Wieland, H, 2006) |
| "The aim of this study was to estimate the effects of various antiglaucoma drugs including betaxolol, timolol, levobunolol, brimonidine, carteolol, dipivefrin, dorzolamide, brinzolamide, latanoprost, unoprostone, and pilocarpine on intracellular free Ca2+ ([Ca2+]i) mobility in cultured bovine corneal endothelial cells." | 3.73 | Effects of antiglaucoma drugs on calcium mobility in cultured corneal endothelial cells. ( Hong, SJ; Wang, HZ; Wu, KY, 2006) |
| "To evaluate the intraocular pressure (IOP) lowering efficacy and safety of Brinzolamide combined with Betaxolol for the Chinese glaucomatous patients." | 3.73 | [Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol]. ( Fang, M; Ge, J; Huang, S; Minbin, Y, 2005) |
| " In the present study, we investigated various commercial antiglaucoma drugs including timolol (0." | 3.72 | Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells. ( Fong, JC; Hong, SJ; Wang, HZ; Wu, KY, 2003) |
| "Claims databases administered by the Régie de l'assurance maladie du Quebec were used to identify incident users of beta-blockers (betaxolol and timolol) and newer antiglaucoma agents (brimonidine, dorzolamide and latanoprost) among patients aged 35 years or older." | 3.72 | Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. ( Assalian, A; Castilloux, AM; Houde, M; LeLorier, J; Tingey, D, 2003) |
| "To report a case of herpes simplex virus reactivation after starting bimatoprost treatment for glaucoma." | 3.71 | Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. ( Kroll, DM; Schuman, JS, 2002) |
| "Of the antiglaucoma drugs investigated, betaxolol displays the greatest L-type VDCC-blocking activity and this may be of clinical relevance." | 3.71 | Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. ( Melena, J; Osborne, NN; Stanton, D, 2001) |
| "We evaluated the effect of betaxolol on the pulmonary function tests of nine patients with glaucoma and chronic obstructive pulmonary disease (COPD) requiring beta-blocker therapy." | 3.67 | Betaxolol in chronic obstructive pulmonary disease. ( Ofner, S; Smith, TJ, 1987) |
| "We evaluated the use of topically administered betaxolol, a cardioselective beta-adrenergic blocking agent, in 11 patients (eight women and three men, 40 to 81 years old) who had asthma and severe glaucoma with increased intraocular pressure despite maximally tolerated medical therapy." | 3.67 | Betaxolol in patients with glaucoma and asthma. ( Berry, DP; Drake, MM; Lustgarten, JS; Podos, SM; Van Buskirk, EM; Weinreb, RN, 1986) |
| "Four hundred sixteen subjects with ocular hypertension (intraocular pressure >/=22 and | 2.75 | The ability of short-wavelength automated perimetry to predict conversion to glaucoma. ( Colen, TP; Lemij, HG; Reus, NJ; van der Schoot, J, 2010) |
| "Glaucoma is a chronic optic neuropathy in which retinal ganglion cells die over a number of years." | 2.42 | Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. ( Casson, R; Chidlow, G; DeSantis, L; Osborne, NN; Schmidt, KG; Wood, JP, 2004) |
| "2% for chronic use in patients with ocular hypertension and glaucoma." | 2.40 | Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. ( Greenfield, DS; Liebmann, JM; Ritch, R, 1997) |
| "Betaxolol is a lipophilic beta-adrenoceptor antagonist relatively selective for beta 1-adrenoceptors with only weak beta 2-blocking activity." | 2.38 | Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. ( Buckley, MM; Clissold, SP; Goa, KL, 1990) |
| "Glaucoma is a group of eye diseases consisting of optic nerve damage with corresponding loss of field vision and blindness." | 1.72 | Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H ( Andreozzi, G; Calderone, V; Caliendo, G; Citi, V; Corvino, A; Fiorino, F; Frecentese, F; Magli, E; Martelli, A; Perissutti, E; Piragine, E; Santagada, V; Severino, B; Sparaco, R, 2022) |
| "Glaucoma is a chronic disease that requires long-term adherence to treatment." | 1.72 | Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction. ( Han, X; Hou, D; Hu, J; Ke, Y; Li, H; Li, W; Lin, H; Liu, H; Rupenthal, ID; Yang, F; Ye, J; Zhao, Y, 2022) |
| "Glaucoma is a serious eye disease that can lead to loss of vision." | 1.48 | Controlled drug delivery for glaucoma therapy using montmorillonite/Eudragit microspheres as an ion-exchange carrier. ( Chen, Y; Duan, H; Hou, D; Li, J; Lv, Z; Tao, Q; Tian, S; Yang, F; Zhao, Y; Zhou, Q, 2018) |
| "Betaxolol was twice as effective at preventing the effect of IgG (34% to 37%) than that of zymosan (14%), regardless of the presence of BAK." | 1.32 | In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. ( Baudouin, C; Blondin, C; Cholley, B; Haeffner-Cavaillon, N; Hamard, P, 2003) |
| "Twenty-nine of these were treated for glaucoma and eight followed for ocular hypertension without treatment." | 1.30 | Five-year follow-up of treated patients with glaucoma using resolution perimetry. ( Martin, L; Wanger, P, 1998) |
| " Very mild eye irritation, which was less than that of betaxolol hydrochloride, was observed particularly with BMO maleate, which is an excellent candidate for safe treatment of glaucoma." | 1.30 | Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma. ( Barros, MD; Bodor, N; Farag, HH; Prokai, L; Somogyi, G; Wu, WM, 1997) |
| "In 35 of the 56 treated glaucoma patients the thresholds improved more than 0." | 1.29 | The effect of treatment on the results of high-pass resolution perimetry in glaucoma. ( Martin-Boglind, L; Wanger, P, 1994) |
| "While adverse effects are uncommon in patients who are otherwise fit and well, doctors should be aware of the implications of the systemic effects of these drugs, particularly the non-selective types, and particularly in the elderly." | 1.29 | The safety of topical beta-blockers in glaucoma treatment. ( Goldberg, I, 1996) |
| " This new pharmaceutical dosage form produces very interesting therapeutic effects with much lower drug concentrations than that commonly used in aqueous commercial eye drops; thus, systemic and local side effects could be minimized." | 1.28 | [Nanocapsules of beta-blocking agents: a new drug carrier in ophthalmology. Application to medical treatment of glaucoma in rabbits]. ( Hoffman, M; Maincent, P; Marchal-Heussler, L; Sirbat, D, 1991) |
| "Betaxolol 0." | 1.27 | Long-term betaxolol therapy in glaucoma patients with pulmonary disease. ( Cherniack, R; Drake, MM; van Buskirk, EM; Weinreb, RN, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (27.72) | 18.7374 |
| 1990's | 29 (28.71) | 18.2507 |
| 2000's | 31 (30.69) | 29.6817 |
| 2010's | 8 (7.92) | 24.3611 |
| 2020's | 5 (4.95) | 2.80 |
| Authors | Studies |
|---|---|
| Sugrue, MF | 1 |
| Elmi Sadr, N | 1 |
| Saber, E | 1 |
| Paknazar, F | 1 |
| Sparaco, R | 3 |
| Citi, V | 3 |
| Magli, E | 3 |
| Martelli, A | 3 |
| Piragine, E | 3 |
| Calderone, V | 3 |
| Andreozzi, G | 3 |
| Perissutti, E | 3 |
| Frecentese, F | 3 |
| Santagada, V | 3 |
| Caliendo, G | 3 |
| Severino, B | 3 |
| Corvino, A | 3 |
| Fiorino, F | 3 |
| Hu, J | 2 |
| Li, H | 2 |
| Zhao, Y | 4 |
| Ke, Y | 2 |
| Rupenthal, ID | 2 |
| Liu, H | 2 |
| Ye, J | 2 |
| Han, X | 2 |
| Yang, F | 4 |
| Li, W | 2 |
| Lin, H | 2 |
| Hou, D | 4 |
| Lešták, J | 1 |
| Fůs, M | 1 |
| Weissová, I | 1 |
| Marešová, K | 1 |
| Allam, A | 1 |
| Elsabahy, M | 1 |
| El Badry, M | 1 |
| Eleraky, NE | 1 |
| Tian, S | 2 |
| Li, J | 2 |
| Tao, Q | 2 |
| Lv, Z | 1 |
| Duan, H | 1 |
| Chen, Y | 2 |
| Zhou, Q | 1 |
| Gui, R | 1 |
| Zang, L | 1 |
| Ping, Q | 1 |
| Okutucu, M | 1 |
| Fındık, H | 1 |
| Arslan, MG | 1 |
| Jain, K | 1 |
| Kumar, RS | 1 |
| Sood, S | 1 |
| Dhyanandhan, G | 1 |
| Fukuchi, T | 1 |
| Kuprjanowicz, L | 1 |
| Karczewicz, D | 1 |
| Plager, DA | 1 |
| Whitson, JT | 4 |
| Netland, PA | 1 |
| Vijaya, L | 2 |
| Sathyan, P | 1 |
| Sood, D | 1 |
| Krishnadas, SR | 1 |
| Robin, AL | 2 |
| Gross, RD | 2 |
| Scheib, SA | 2 |
| Scott, H | 2 |
| Dickerson, JE | 2 |
| Grieshaber, MC | 1 |
| Flammer, J | 3 |
| van der Schoot, J | 1 |
| Reus, NJ | 1 |
| Colen, TP | 1 |
| Lemij, HG | 1 |
| Rahman, MQ | 1 |
| Abeysinghe, SS | 1 |
| Kelly, S | 1 |
| Roskell, NS | 1 |
| Shannon, PR | 1 |
| Abdlseaed, AA | 1 |
| Montgomery, DM | 1 |
| Kóthy, P | 1 |
| Holló, G | 3 |
| Vainio-Jylhä, E | 2 |
| Vuori, ML | 2 |
| Nummelin, K | 1 |
| Kamal, D | 1 |
| Garway-Heath, D | 1 |
| Ruben, S | 1 |
| O'Sullivan, F | 1 |
| Bunce, C | 1 |
| Viswanathan, A | 1 |
| Franks, W | 1 |
| Hitchings, R | 1 |
| Lin, JC | 1 |
| Samuel, F | 1 |
| Katz, LJ | 2 |
| Spaeth, GL | 2 |
| Hoop, J | 1 |
| Cantor, LB | 2 |
| Hong, SJ | 4 |
| Wu, KY | 4 |
| Wang, HZ | 4 |
| Fong, JC | 1 |
| Blondin, C | 1 |
| Hamard, P | 1 |
| Cholley, B | 1 |
| Haeffner-Cavaillon, N | 1 |
| Baudouin, C | 1 |
| Houde, M | 1 |
| Castilloux, AM | 1 |
| Tingey, D | 1 |
| Assalian, A | 1 |
| LeLorier, J | 1 |
| Leske, MC | 1 |
| Heijl, A | 1 |
| Hyman, L | 1 |
| Bengtsson, B | 1 |
| Komaroff, E | 1 |
| Osborne, NN | 2 |
| Wood, JP | 1 |
| Chidlow, G | 1 |
| Casson, R | 1 |
| DeSantis, L | 2 |
| Schmidt, KG | 1 |
| Yarangümeli, A | 1 |
| Kural, G | 1 |
| Ignat, F | 1 |
| Turaçli, ME | 1 |
| Tekeli, O | 1 |
| Erb, C | 1 |
| Schröder, H | 1 |
| Faulkner, R | 1 |
| McCue, B | 1 |
| Curtis, M | 1 |
| Wieland, H | 1 |
| Chastain, J | 1 |
| Sanders, M | 1 |
| Przydryga, J | 1 |
| Dahlin, DC | 1 |
| Minbin, Y | 1 |
| Fang, M | 1 |
| Ge, J | 1 |
| Huang, S | 1 |
| Easton, PJ | 1 |
| Roarty, JD | 1 |
| Landry, TA | 1 |
| Hua, SY | 1 |
| Woodside, AM | 1 |
| Bergamini, MV | 1 |
| Nagata, T | 1 |
| Ueno, S | 1 |
| Morita, H | 1 |
| Kubota, T | 1 |
| Toyohira, Y | 1 |
| Tsutsui, M | 1 |
| Tawara, A | 1 |
| Yanagihara, N | 1 |
| Harrison, R | 1 |
| Remis, LL | 1 |
| Epstein, DL | 2 |
| Johns, MD | 1 |
| Ponte, CD | 1 |
| Harris, A | 1 |
| Sergott, RC | 1 |
| Martin, BJ | 1 |
| Martin-Boglind, L | 1 |
| Wanger, P | 3 |
| Zimmerman, TJ | 1 |
| Frishman, WH | 1 |
| Fuksbrumer, MS | 1 |
| Tannenbaum, M | 1 |
| Diggory, P | 3 |
| Heyworth, P | 2 |
| Chau, G | 2 |
| McKenzie, S | 2 |
| Sharma, A | 2 |
| O'Donnell, BF | 1 |
| Foulds, IS | 1 |
| Nyman, K | 1 |
| Luke, I | 1 |
| Goldberg, I | 2 |
| Gale, AE | 1 |
| Gillies, WE | 2 |
| Brooks, AM | 2 |
| Greenfield, DS | 1 |
| Liebmann, JM | 1 |
| Ritch, R | 1 |
| Farag, HH | 1 |
| Wu, WM | 1 |
| Barros, MD | 1 |
| Somogyi, G | 1 |
| Prokai, L | 1 |
| Bodor, N | 1 |
| Martin, L | 1 |
| Morrison, JC | 1 |
| Nylander, KB | 1 |
| Lauer, AK | 1 |
| Cepurna, WO | 1 |
| Johnson, E | 1 |
| Cassels-Brown, A | 1 |
| Vail, A | 1 |
| Hillman, JS | 1 |
| Collignon-Brach, J | 1 |
| Demailly, P | 1 |
| Graves, SA | 1 |
| Wolfhagen, FH | 1 |
| van Neerven, JA | 1 |
| Groen, FC | 1 |
| Ouwendijk, RJ | 1 |
| Sponsel, WE | 1 |
| Terry, S | 1 |
| Khuu, HD | 1 |
| Lam, KW | 1 |
| Frenzel, H | 1 |
| Waldock, A | 1 |
| Snape, J | 1 |
| Graham, CM | 1 |
| Pyykkö, K | 1 |
| Huupponen, R | 1 |
| Melena, J | 1 |
| Stanton, D | 1 |
| Schweitzer, I | 1 |
| Maguire, K | 1 |
| Tuckwell, V | 1 |
| Grehn, F | 1 |
| Kroll, DM | 1 |
| Schuman, JS | 1 |
| Potocký, M | 1 |
| Vodrázková, E | 1 |
| Duch, S | 1 |
| Duch, C | 1 |
| Pastó, L | 1 |
| Ferrer, P | 1 |
| Marchal-Heussler, L | 1 |
| Sirbat, D | 1 |
| Hoffman, M | 1 |
| Maincent, P | 1 |
| Messmer, C | 1 |
| Stümpfig, D | 1 |
| Dorigo, MT | 1 |
| Cerin, O | 1 |
| Fracasso, G | 1 |
| Altafini, R | 1 |
| Martin-Boglind, LM | 1 |
| Graves, A | 1 |
| Buckley, MM | 1 |
| Goa, KL | 1 |
| Clissold, SP | 1 |
| Collignon, P | 1 |
| James, IM | 1 |
| Pillunat, LE | 2 |
| Stodtmeister, R | 2 |
| Vogel, R | 1 |
| Tipping, R | 1 |
| Kulaga, SF | 1 |
| Clineschmidt, CM | 1 |
| Swietliczko, I | 1 |
| Rojek, A | 1 |
| Sempińska-Szewczyk, J | 1 |
| Toczyska-Rozentryt, E | 1 |
| Soll, DB | 1 |
| Saxon, AM | 1 |
| Richards, RD | 1 |
| Nelson, WL | 1 |
| Kuritsky, JN | 1 |
| Berger, WE | 1 |
| West, RH | 1 |
| Lesar, TS | 1 |
| Tierney, DW | 1 |
| Thygesen, J | 1 |
| Feghali, JG | 1 |
| Kaufman, PL | 1 |
| Radius, RL | 1 |
| Mandell, AI | 1 |
| Lynch, MG | 1 |
| Brown, RH | 1 |
| Nguyen, H | 1 |
| Drake, MM | 3 |
| Ofner, S | 1 |
| Smith, TJ | 1 |
| Long, DA | 1 |
| Johns, GE | 1 |
| Mullen, RS | 1 |
| Bowe, RG | 1 |
| Alexander, D | 1 |
| Weiss, MJ | 1 |
| Masi, RJ | 1 |
| Charap, AD | 1 |
| Eto, CY | 1 |
| Weinreb, RN | 2 |
| van Buskirk, EM | 2 |
| Cherniack, R | 1 |
| Stewart, RH | 1 |
| Kimbrough, RL | 1 |
| Ward, RL | 1 |
| Roholt, PC | 1 |
| Berry, DP | 1 |
| Lustgarten, JS | 1 |
| Podos, SM | 1 |
| Harris, LS | 1 |
| Greenstein, SH | 1 |
| Bloom, AF | 1 |
| Orlando, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension[NCT00061542] | Phase 3 | 105 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Evaluation of Macular Thickness in Patients With Glaucoma in Use of Topical Prostaglandin Analogue Undergoing Trabeculectomy With Mitomycin C[NCT06000280] | 37 participants (Actual) | Interventional | 2021-01-04 | Completed | |||
| Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension[NCT00061516] | Phase 3 | 78 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for betaxolol and Glaucoma
| Article | Year |
|---|---|
New approaches to antiglaucoma therapy.
Topics: Adenosine; Animals; Antihypertensive Agents; Cannabinoids; Drug Design; Endothelins; Glaucoma; Guany | 1997 |
[Neuroprotection in glaucoma].
Topics: Betaxolol; Brimonidine Tartrate; Disease Progression; Glaucoma; Guanidines; Humans; Memantine; Neuro | 2007 |
Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans; Intraocular Pressure; Timolol; Visual Fiel | 2010 |
Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial.
Topics: Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Disease Progression; Glaucoma; Humans | 2004 |
Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma.
Topics: Animals; Betaxolol; Calcium; Glaucoma; Humans; Ischemia; Retina; Sodium; Sodium-Calcium Exchanger; T | 2004 |
Are there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other beta-blockers in the treatment of glaucoma?
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans; Ophthalmic Soluti | 2004 |
Treatment of glaucoma.
Topics: Betaxolol; Epinephrine; Glaucoma; Glaucoma, Open-Angle; Humans; Hydroxydopamines; Laser Therapy; Lev | 1984 |
Acute pulmonary edema associated with ocular metipranolol use.
Topics: Aged; Betaxolol; Clinical Trials as Topic; Female; Glaucoma; Humans; Metipranolol; Ophthalmic Soluti | 1995 |
Topical ophthalmic beta blockers: a comparative review.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Carteolol; Drug Tolerance; | 1993 |
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Humans; Levobu | 1994 |
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Clinical Tr | 1997 |
Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.
Topics: Betaxolol; Eye Diseases; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions | 1990 |
Pharmacologic effects of beta-blocking agents used in the management of glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Heart Rate; Humans; Intraocular Pressur | 1989 |
Betaxolol.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans; Intraocular Pressure; Propanolamines; Time | 1989 |
Comparison of ophthalmic beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Betaxolol; Cardiovascular System; Clinical Trials as Topic; Glaucoma; H | 1987 |
32 trials available for betaxolol and Glaucoma
| Article | Year |
|---|---|
The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy.
Topics: Betaxolol; Brimonidine Tartrate; Capsule Opacification; Glaucoma; Humans; Intraocular Pressure; Lens | 2022 |
Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness.
Topics: Adult; Antihypertensive Agents; Betaxolol; Choroid; Glaucoma; Humans; Latanoprost; Middle Aged; Sulf | 2019 |
Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial.
Topics: Antihypertensive Agents; Betaxolol; Child; Child, Preschool; Double-Blind Method; Female; Gels; Glau | 2009 |
The ability of short-wavelength automated perimetry to predict conversion to glaucoma.
Topics: Aged; Antihypertensive Agents; Betaxolol; Double-Blind Method; Female; Follow-Up Studies; Glaucoma; | 2010 |
Does glaucoma medication influence the diameter of the retinal arteriole in the human eye? (A pilot study using the retinal vessel analyser).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Art | 2001 |
Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Disease Progression; Double-Blind Method; Femal | 2002 |
Results of the betaxolol versus placebo treatment trial in ocular hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Double-Blind Method; Female; Glaucoma; Humans; Intraoc | 2003 |
The effect of topical glaucoma medications evaluated by perimetry.
Topics: Administration, Topical; Antihypertensive Agents; Betaxolol; Clonidine; Epinephrine; Glaucoma; Human | 2003 |
Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial.
Topics: Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Disease Progression; Glaucoma; Humans | 2004 |
[Early Manifest Glaucoma Trial update 2004].
Topics: Aged; Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Disease Progression; Female; Fo | 2005 |
Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carbonic Anhydrase Inhibitors; Child; Child, Preschool; Dose | 2008 |
Betaxolol and timolol.
Topics: Adrenergic beta-Antagonists; Betaxolol; Clinical Trials as Topic; Glaucoma; Humans; Intraocular Pres | 1984 |
Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma.
Topics: Arteries; Betaxolol; Blood Flow Velocity; Cross-Over Studies; Double-Blind Method; Female; Glaucoma; | 1995 |
Unsuspected bronchospasm in association with topical timolol--a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement?
Topics: Aged; Aged, 80 and over; Airway Resistance; Betaxolol; Bronchial Spasm; Female; Forced Expiratory Vo | 1994 |
Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients.
Topics: Administration, Topical; Aged; Aged, 80 and over; Betaxolol; Female; Forced Expiratory Volume; Glauc | 1993 |
A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Australia; Bet | 1996 |
Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma.
Topics: Aged; Antihypertensive Agents; Betaxolol; Double-Blind Method; Female; Glaucoma; Humans; Intraocular | 1998 |
Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Betaxolol; Blood | 2000 |
[Betoptic, a new possibility in the treatment of glaucoma].
Topics: Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Glaucoma; Humans; Intraocular Pressure; Timolol | 1992 |
Changes in depressive status associated with topical beta-blockers.
Topics: Adult; Aged; Betaxolol; Brain; Depression; Double-Blind Method; Female; Glaucoma; Humans; Male; Midd | 1992 |
Influence of betaxolol and timolol on the visual fields of patients with glaucoma.
Topics: Aged; Betaxolol; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle A | 1991 |
Cardiovascular effects of befunolol, betaxolol and timolol eye drops.
Topics: Adrenergic beta-Antagonists; Betaxolol; Blood Pressure; Double-Blind Method; Electrocardiography; Fe | 1990 |
The effect of topical antiglaucoma drugs on the results of high-pass resolution perimetry.
Topics: Administration, Topical; Aged; Betaxolol; Double-Blind Method; Epinephrine; Female; Glaucoma; Humans | 1991 |
Changing therapy from timolol to betaxolol. Effect on intraocular pressure in selected patients with glaucoma. Timolol-Betaxolol Study Group.
Topics: Adrenergic beta-Antagonists; Betaxolol; Blood Pressure; Glaucoma; Humans; Intraocular Pressure; Prop | 1989 |
[Use of Betaxolol in patients with glaucoma and chronic nonspecific diseases of the respiratory system].
Topics: Aged; Betaxolol; Clinical Trials as Topic; Female; Glaucoma; Humans; Intraocular Pressure; Lung Dise | 1989 |
Betaxolol eye drops as a safe medication to lower intraocular pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Clinical Trials as Topic; Cornea; F | 1987 |
Comparison of ophthalmic beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Betaxolol; Cardiovascular System; Clinical Trials as Topic; Glaucoma; H | 1987 |
A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Clinical Trials as Topic; Double-Blind Method; Female | 1988 |
Topical beta-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Central Nervous System | 1988 |
Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure.
Topics: Betaxolol; Clinical Trials as Topic; Double-Blind Method; Glaucoma; Humans; Intraocular Pressure; Le | 1988 |
[Effect of nonspecific and cardioselective beta receptor blockers on the formation of aqueous humor. An oculopressure tonometry study].
Topics: Adult; Betaxolol; Clinical Trials as Topic; Double-Blind Method; Female; Glaucoma; Humans; Intraocul | 1988 |
Betaxolol vs timolol. A six-month double-blind comparison.
Topics: Adult; Aged; Betaxolol; Clinical Trials as Topic; Double-Blind Method; Female; Glaucoma; Humans; Int | 1986 |
56 other studies available for betaxolol and Glaucoma
| Article | Year |
|---|---|
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H
Topics: Antiglaucoma Agents; Betaxolol; Gasotransmitters; Glaucoma; Humans; Hydrogen Sulfide | 2022 |
Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction.
Topics: Betaxolol; Cornea; Drug Carriers; Glaucoma; Humans; Intraocular Pressure; Nanoparticles; Particle Si | 2022 |
Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction.
Topics: Betaxolol; Cornea; Drug Carriers; Glaucoma; Humans; Intraocular Pressure; Nanoparticles; Particle Si | 2022 |
Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction.
Topics: Betaxolol; Cornea; Drug Carriers; Glaucoma; Humans; Intraocular Pressure; Nanoparticles; Particle Si | 2022 |
Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction.
Topics: Betaxolol; Cornea; Drug Carriers; Glaucoma; Humans; Intraocular Pressure; Nanoparticles; Particle Si | 2022 |
Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma.
Topics: Betaxolol; Carteolol; Evoked Potentials, Visual; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular | 2020 |
Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma.
Topics: Animals; Betaxolol; Drug Carriers; Drug Delivery Systems; Gels; Glaucoma; Hydrogen-Ion Concentration | 2021 |
Controlled drug delivery for glaucoma therapy using montmorillonite/Eudragit microspheres as an ion-exchange carrier.
Topics: Animals; Bentonite; Betaxolol; Biological Availability; Cell Death; Chorioallantoic Membrane; Delaye | 2018 |
Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma.
Topics: Administration, Topical; Animals; Aqueous Humor; Bentonite; Betaxolol; Cell Survival; Chitosan; Corn | 2018 |
Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy.
Topics: Administration, Ophthalmic; Animals; Antihypertensive Agents; Betaxolol; Chickens; Chitosan; Chorioa | 2013 |
[Current trend of glaucoma medication with various eye drops].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolo | 2013 |
Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database.
Topics: Algorithms; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Clinical Protocols; Databases, | 2011 |
Delaying glaucoma.
Topics: Antihypertensive Agents; Betaxolol; Disease Progression; Glaucoma; Humans; Intraocular Pressure; Las | 2002 |
Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells.
Topics: Animals; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Calcium; Carteolol; Cell Death; D | 2003 |
In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system.
Topics: Adrenergic beta-Antagonists; Benzalkonium Compounds; Betaxolol; Carteolol; Complement System Protein | 2003 |
Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Betaxolo | 2003 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glau | 2004 |
Infantile glaucoma in a patient with Rothmund-Thomson syndrome.
Topics: Adolescent; Antihypertensive Agents; Betaxolol; Female; Glaucoma; Humans; Intraocular Pressure; Roth | 2004 |
[Increased intraocular pressure in asthma patients].
Topics: Adrenergic beta-Agonists; Anti-Asthmatic Agents; Asthma; Betaxolol; Glaucoma; Glucocorticoids; Human | 2005 |
Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration.
Topics: Administration, Topical; Adult; Aged; Animals; Antihypertensive Agents; Betaxolol; Biological Availa | 2006 |
Effects of antiglaucoma drugs on calcium mobility in cultured corneal endothelial cells.
Topics: Animals; Antihypertensive Agents; Betaxolol; Calcium; Endothelium, Corneal; Glaucoma; Levobunolol; M | 2006 |
[Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Betaxolol; Carbonic Anhydrase Inhibitors; Female; | 2005 |
Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells.
Topics: Animals; Betaxolol; Carteolol; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Endothelia | 2007 |
A cardiovascular benefit of ophthalmic beta-blockade.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Atrial Fibrillation; Betaxolol; Biological Availabil | 2007 |
Pharmacological neuroprotection for glaucoma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Eye; Glaucoma; Humans; Neuroprotect | 2007 |
Direct inhibition of N-methyl-D-aspartate (NMDA)-receptor function by antiglaucomatous beta-antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Calcium; Dose-Response Relationship, Drug; Excitato | 2008 |
The effect of treatment on the results of high-pass resolution perimetry in glaucoma.
Topics: Aged; Betaxolol; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Male; Ocula | 1994 |
Contact allergy to beta-blocking agents in ophthalmic preparations.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Dermatitis, Allergic Contact; Drug Eruptions; Glaucoma | 1993 |
Intraocular pressure reduction with topically administered pilocarpine, timolol and betaxolol in normal tension glaucoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Analysis of Variance; Betaxolol; Female; Glaucoma; | 1993 |
The safety of topical beta-blockers in glaucoma treatment.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Betaxolol; Glaucoma; Humans; Levobunolol; Ophthalmic | 1996 |
The safety of topical beta-blockers in glaucoma treatment.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans | 1996 |
Effects of pilocarpine and other antiglaucoma drugs on cultured human Tenon's fibroblast cells.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Cell Division; Cells, Cultured; Eye; Fibroblasts; | 1997 |
Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Eye; Glaucoma; Intraocular | 1997 |
Five-year follow-up of treated patients with glaucoma using resolution perimetry.
Topics: Aged; Betaxolol; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular | 1998 |
Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Clonidine; Disease Model | 1998 |
[A long-term study of the visual fields in patients treated with betaxolol and timolol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Belgium; Betaxolol; Female; Glaucoma; Glaucoma, Angle-Clos | 1998 |
Severe nausea and vomiting with timolol eye drops.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Betaxolol; Female; Glaucoma; Humans; Ind | 1998 |
Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Biological Availability; Chr | 1999 |
Plasma concentration of topically applied betaxolol in elderly glaucoma patients.
Topics: Absorption; Administration, Topical; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihyper | 2001 |
Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Betaxolol; Calcium; Calcium Channels; | 2001 |
Antiglaucoma medication and clinical depression.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Depressive Disorder, Major; Glaucoma; Humans; Male; Op | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; | 2001 |
Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma.
Topics: Acyclovir; Aged; Amides; Anti-Infective Agents; Anti-Inflammatory Agents; Antihypertensive Agents; A | 2002 |
[Nanocapsules of beta-blocking agents: a new drug carrier in ophthalmology. Application to medical treatment of glaucoma in rabbits].
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Capsules; Colloids; Dosage Forms; Dose-Response Rel | 1991 |
Cardiovascular and pulmonary effects of beta-blocking agents: implications for their use in ophthalmology.
Topics: Adrenergic beta-Antagonists; Age Factors; Betaxolol; Cardiovascular System; Drug Interactions; Glauc | 1989 |
Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs.
Topics: Acetazolamide; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Glaucoma, Open-Angle; Hu | 1989 |
Drugs and glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carbonic Anhydrase Inhibitors; Drug Combinations; Drug Impla | 1986 |
Glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Glaucoma, Open-Angle; Humans; Infant, Newborn; Las | 1987 |
Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans; Ocular Hypertension; Product Surveillance, | 1987 |
Betaxolol in patients with glaucoma and asthma.
Topics: Adrenergic beta-Antagonists; Asthma; Betaxolol; Glaucoma; Humans; Propanolamines | 1987 |
New topical beta-blockers for glaucoma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Humans; Metipr | 1987 |
Betaxolol and levobunolol: new beta-blocking antiglaucoma agents.
Topics: Adrenergic beta-Antagonists; Betaxolol; Chemical Phenomena; Chemistry; Glaucoma; Humans; Intraocular | 1987 |
[Betaxolol. A new beta blockader with beta-1-selectivity in glaucoma treatment].
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Humans; Propanolamines | 1988 |
Betaxolol in chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Forced Expiratory Volume; Glaucoma; Humans; Intraocula | 1987 |
Long-term betaxolol therapy in glaucoma patients with pulmonary disease.
Topics: Aged; Asthma; Betaxolol; Female; Glaucoma; Humans; Intraocular Pressure; Lung Diseases; Male; Middle | 1988 |
Betaxolol and restrictive airway disease. Case report.
Topics: Aged; Betaxolol; Female; Glaucoma; Humans; Propanolamines; Respiration Disorders | 1987 |
Betaxolol in patients with glaucoma and asthma.
Topics: Administration, Topical; Adult; Aged; Asthma; Betaxolol; Female; Glaucoma; Humans; Lung Volume Measu | 1986 |
Respiratory difficulties with betaxolol.
Topics: Aged; Airway Obstruction; Asthma; Betaxolol; Female; Glaucoma; Humans; Male; Middle Aged; Ophthalmic | 1986 |
Clinical depression associated with betaxolol.
Topics: Betaxolol; Depression; Female; Glaucoma; Humans; Middle Aged; Propanolamines | 1986 |